Alexion, Astrazeneca Rare Disease, Completes Acquisition Of Logicbio® Therapeutics
Acquiring Company
Alexion
Acquired Company
LogicBioTherapeutics
Description
Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
Who to call at Alexion, and when
When Alexion changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Alexion raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alexion, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alexion. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alexion makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired LogicBioTherapeutics?
LogicBioTherapeutics was acquired by Alexion. The deal was reported on November 16, 2022. Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. Alexion is privately held and operates in Biotechnology.
When did Alexion acquire LogicBioTherapeutics?
Alexion's acquisition of LogicBioTherapeutics was reported on November 16, 2022. Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does LogicBioTherapeutics do?
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare diseases. Learn More It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.